durvalumab,tremelimumab
astrazeneca
[]
infinity trial (phii): preoperative t300/d (tremedurva) for 3 months achieved a pcr rate of 60% in patients with dmmr / msi-h gac/gejac #ascogi23 
Gastrointestinal Medical Oncologist. Professor of Medicine and Attending Physician at University of Nuevo Leon Cancer Center.  🇲🇽